Iovance looks to advance its non-small cell lung cancer therapy

Iovance Biotherapeutics completed a preliminary analysis of the Phase II trial for its autologous tumour-infiltrating lymphocyte (TIL) therapy, Lifileucel (LN-145), in patients with metastatic non-small cell lung cancer (NSCLC) after a US Food and Drug Administration (FDA) review found the trial design may be suitable for accelerated approval.